BEYONTTRA
Live / Applied — Fifth extension granted (statement of use) (as of 02 Feb 2026)
What this means for you
Not registered yet, but its 28 Feb 2022 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 97288149
- Mark type
- Stylized text
- Filed
- 28 Feb 2022
- Published for opposition
- 17 Jan 2023
- Attorney of record
- Jessica L. Rothstein
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceuticals for use in the treatment of oncological, cardiological, dermatological, neurological, genetic, orthopedic and metabolic diseases and disorders
Owner
- BridgeBio Pharma, Inc., Palo Alto, CA, US
- BridgeBio Pharma, Inc., Palo Alto, CA, US
Prosecution history
- 02 Feb 2026 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 02 Feb 2026 — SOU EXTENSION 5 GRANTED
- 12 Sept 2025 — SOU EXTENSION 5 FILED
- 30 Jan 2026 — CASE ASSIGNED TO INTENT TO USE PARALEGAL
- 12 Sept 2025 — SOU TEAS EXTENSION RECEIVED
- 24 Feb 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 23 Feb 2025 — SOU EXTENSION 4 GRANTED
- 23 Feb 2025 — SOU EXTENSION 4 FILED
- 23 Feb 2025 — SOU TEAS EXTENSION RECEIVED
- 28 Jul 2024 — SOU EXTENSION 3 GRANTED
- 28 Jul 2024 — SOU EXTENSION 3 FILED
- 28 Jul 2024 — SOU TEAS EXTENSION RECEIVED
- 09 Feb 2024 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 08 Feb 2024 — SOU EXTENSION 2 GRANTED
- 08 Feb 2024 — SOU EXTENSION 2 FILED